Introduction {#s1}
============

Blastocyst complementation is a biological technique used to complement genetically deficient organs or tissues by microinjecting stem cells into blastocyst-stage embryos of organogenesis-disabled mice. The first report of this technique described the complementation of T- and B-lymphocytes in Rag-deficient (*Rag2*^−/−^) mice by microinjecting intact mouse embryonic stem cells (mESCs) into blastocyst-stage embryos \[[@r4]\]. More recently, Kobayashi *et al.* (2010) succeeded in generating interspecific chimeras, namely PDX1-deficient mice with rat pancreata \[[@r13]\]. Additionally, rat ESCs injected into mouse blastocysts differentiated into rat spermatozoa in nude mice \[[@r11]\]. These studies demonstrate that blastocyst complementation is effective for generating three-dimensional and functional cells or organs *in vivo*. To build on this previous work, we aimed to regenerate of various organs via blastocyst complementation using human ES/iPS cells.

By injecting human pluripotent stem (PS) cells into chicken \[[@r6]\] and mouse blastocysts \[[@r13]\], groups in the US and Israel have successfully developed chimeric embryos. In Japan, it is possible to generate chimeras from specified embryos by combining animal blastocysts with human PS cells (animal-human PS chimera). However, the regulations regarding the production of animal-human PS chimeras are extremely strict, as human PS cells may form gametes or become incorporated into the brain. Therefore, the Japanese government is apprehensive that this may lead to human-like intelligence in animals or that they may form human spermatozoa and oocytes, though the study on development of animal-human PS chimera was lifted on March 1, 2019.

PRDM14 is a sequence-specific transcriptional regulator that plays key roles in promoting primordial germ cell specification and safeguarding the pluripotency of mESCs \[[@r17]\]. During mouse embryogenesis, the *Prdm14* gene is expressed in preimplantation embryos, where its asymmetric expression promotes the allocation of cells toward various functions in the pluripotent inner cell mass \[[@r3]\]. PRDM14 deficiency in mice results in sterility associated with early germ cell deficiency, as cells allocated to become primordial germ cells fail to reacquire the expression of key pluripotency factors in order to undergo epigenetic reprogramming \[[@r25]\].

The *Otx2* gene is a homeobox gene expressed in the rostral brain regions and is thought to define the anterior regions of the embryo \[[@r1]\]. *Otx2* homozygous mutants exhibit defects of the earliest OTX2 functions in the visceral endoderm, and heterozygous mutants show defects of their cephalic neural crest cells \[[@r18]\]. Additionally, knockout of *Otx2* resulted in the failure of the brain to form properly in the embryo \[[@r22]\].

Recently, gene targeting using the CRISPR/Cas9 system has become established as a means of simply editing mouse genomic DNA \[[@r5], [@r9]\]. Thus, we hypothesized that blastocyst complementation using human ES/iPS cells that lack the *Prdm14* and *Otx2* genes may address the concerns regarding blastocyst complementation in Japan. Therefore, we conducted experiments confirming that mESCs having CRISPR/Cas9-induced deletions of both *Prdm14* and *Otx2* genes do not contribute to either the gametes or the brain when used for pancreatic (PDX1-deficient) blastocyst complementation.

Materials and Methods {#s2}
=====================

Culture of mESCs
----------------

Undifferentiated donor GFP-expressing mESCs (G-mESCs) were purchased from the Center for Developmental Biology, RIKEN (Kobe, Japan), and maintained on gelatin-coated dishes with feeder cells in DMEM (Cat No. 10829018, Gibco, Ireland) with 10% KnockOut^TM^ Serum Replacement (Cat No 10828-028, Gibco), 0.1 mM 2-mercaptoethanol (Cat No. 60-24-2, Sigma-Aldrich, St. Louis, MO, USA), 0.1 mM nonessential amino acids (Cat No. 11140050, Gibco), and 1,000 units/ml of mouse leukemia inhibitory factor (Cat No. ESG1107, Chemicon, Temecula, CA, USA).

Gene targeting by CRISPR/Cas9
-----------------------------

Mouse *Prdm14* and *Otx2* genomic clones were isolated from the C57BL/6JJcl strain mouse genomic clone library. PRDM14 CRISPR/Cas9KO plasmid (h) (Cat No. sc-404426, Santa Cruz Biotechnology, Dallas, TX, USA) was used for gene targeting. The targeting vector (Cat No. sc-404426-HDR; Santa Cruz Biotechnology) was modified as follows. Gene targeting constructs of *Prdm14* were generated in a vector containing mouse Pgk promoter-neomycin, which was substituted for the exon 2 coding region of the *Prdm14* gene ([Fig. 1A](#fig_001){ref-type="fig"}Fig. 1.Targeting of *Prdm14* and *Otx2* genes. A. Schematic representation of the *Prdm14* gene and targeting strategy. The red-colored bar indicates the position of the probe for genomic Southern blot analysis using SmaI and BamHI digested samples (mutated allele, 3,730 bp; wild-type allele, 5,750 bp). B. Genomic DNA from ES cells was digested with SmaI and BamHI and subjected to hybridization with the probe. Lane 1, markers; Lanes 2--5, wild type; Lanes 6, gene-targeted ES clones; Lane 7, wild type; Lane 8, none; Lane 9, gene-targeted ES clones; Lane 10, wild type; Lane 11, gene-targeted ES clones. C. Schematic representation of the *Otx2* gene and secondary targeting strategy. The red-colored bar indicates the position of the probe for genomic Southern blot analysis using EcoRV and ScaI digested samples (mutated allele, 4,041 bp; wild-type allele, 6,728 bp). D. Genomic DNA from ES cells was digested with EcoRV and ScaI and subjected to hybridization with the probe. Lane 1, markers; Lanes 2 and 3, gene-targeted ES clones; Lane 4, wild type; Lane 5, gene-targeted ES clone. E. Establishment of ES cells without the *Prdm14* and *Otx2* genes. Scale bars represent 200 *µ*m. F. Chromosome banding of the ES cells without the *Prdm14* and *Otx2* genes. Scale bars represent 50 *µ*m. G. Chimeric mice generated from the ES cells without the *Prdm14* and *Otx2* genes.). 5 × 10^6^ G-mESCs were electroporated with 15 *µ*g of linearized targeting construct in 100 *µ*l solution V (Nucleofector Kit, Lonza, Tokyo, Japan) and one pulse of 800 V/3 *µ*F with an Amaxa Nucleofector I (Lonza). G-mESCs were then subjected to positive selection with 250 *µ*g/ml neomycin (Cat No. 10131035, Thermo Fisher Scientific, Waltham, MA, USA). After 7--10 days, 83 clones were isolated and screened for the presence of the targeted allele. The presence of the correct homologous recombination was confirmed by Southern blotting using a neomycin inner probe (5'-GATCGGCCATTGAACAAGAT-3' and 5'-CTCGTCCTGCAGTTCATTCA-3') ([Fig. 1B](#fig_001){ref-type="fig"}). Additionally, PCR screening was performed using genotyping primers (5'-TCCTGCCTCGGGTTCACCTA-3' \[forward\], 5'-CCAACCTCAGGTCGTCCTCC-3' \[reverse\], and 5'-CCTTGCTCTGGTCAACCAGGTT-3' \[Neo\]) to exclude heterozygote clones. After the establishment of PRDM14-deficient G-mESCs, gene targeting of *Otx2* was also performed by CRISPR/Cas9. An OTX2 CRISPR/Cas9KO plasmid (Cat No. sc-422085, Santa Cruz Biotechnology) was used for gene targeting. The targeting vector (Cat No. sc-422085-HDR, Santa Cruz Biotechnology) was modified as follows. Gene targeting constructs of *Otx2* were generated in the vector containing Mc1 promoter-puromycin, which was substituted for the exon 4 coding region of the *Otx2* gene ([Fig. 1C](#fig_001){ref-type="fig"}). 5 × 10^6^ G-mESCs without *Prdm14* gene were electroporated with 15 *µ*g of linearized targeting construct under the same conditions as used previously. G-mESCs were then subjected to positive selection with 2 *µ*g/ml puromycin (Cat No. 10131035, Thermo Fisher Scientific, Waltham, MA, USA). After 7--10 days, 51 clones were isolated and screened for the presence of the targeted allele. After targeting of the *Otx2* gene, the occurrence of the correct homologous recombination was confirmed by Southern blotting using a puromycin inner probe (5'-ACAGATGGAAGGCCTCCTG-3' and 5'-GCTCGTAGAAGGGGAGGTTG-3') ([Fig. 1D](#fig_001){ref-type="fig"}). Additionally, PCR screening was performed using genotyping primers (5'- ATCTGCAACTCCTTTAAAAG-3' \[forward\], 5'-AATGCTCTGTGGCACTCGGC-3' \[reverse\], and 5'- CCGGCTGGATGATCCTCCAG-3' \[Puro\]) to exclude heterozygote clones. Then, *Prdm14* and *Otx2* gene double-knockout G-mESCs were established ([Fig. 1E](#fig_001){ref-type="fig"}). The number of chromosomes was determined in 50 cells from each of these original G-mESCs, in accordance with the protocol of Sugawara *et al.* (2006) \[[@r20]\]. The results indicated that 80--90% of the G-mESCs had the correct number ([Fig. 1F](#fig_001){ref-type="fig"}). Therefore, these G-mESCs were used to generate chimeras ([Fig. 1G](#fig_001){ref-type="fig"}), which were *Pdx1*^−/−^ mice complemented by G-mESCs without the *Prdm14* and *Otx2* genes (*PPO* mice).

Embryo culture and manipulation to prepare Pdx1^−/−^ blastocyst complementation
-------------------------------------------------------------------------------

*Pdx1*^+/−^ mice, which were developed by Hashimoto *et al.* \[[@r7]\], were backcrossed onto the IQI/Jic strain (CIEA, Kawasaki, Japan) for more than 5 generations. Then, the preparation of *Pdx1* heterozygous intercrossing embryos was carried out in accordance with published protocols \[[@r16]\]. In brief, embryos for injection were collected upon crossing *Pdx1*^+/−^ male mice and superovulated *Pdx1*^+/−^ female mice. Their embryos were cultured with potassium simplex optimized medium (KSOM; ARK Resource Co., Ltd., Kumamoto, Japan) until the blastocyst stage. For micromanipulation, G-mESCs were trypsinized and suspended in G-mESCs culture medium. Approximately 10 G-mESCs were introduced into blastocyst cavities near the ICM. After blastocyst injection, mouse blastocysts were transferred into the uteri of pseudopregnant recipient ICR mice at an embryonic age of 2.5 days.

Animal husbandry
----------------

All the mice were provided with exclusive feed for laboratory animals (CA-1, CLEA, Tokyo, Japan) and tap water *ad libitum*. After weaning, two to three mice were kept in an open cage. The animal room was maintained at 24 ± 2°C with 55 ± 10% relative humidity and 12 h of artificial lighting from 08:00 to 20:00 and was kept under specific pathogen-free conditions, which were the same as in a previous study \[[@r8]\]. The glucose tolerance test was performed when mice were 6 weeks of age. The Animal Committee of the Central Institute for Experimental Animals approved this study (Permit No. 14050A).

Genotyping
----------

The *Pdx1* mutation and wild type were distinguished by genotyping PCR using mouse tail to exclude the wild type because the genotyping PCR was unable to distinguish between the *Pdx1*^−/−^ and *Pdx1*^+/−^ mice by the contribution of the donor G-mESCs to the tail of chimeric mouse. The genotyping PCR was performed in accordance with a previous report \[[@r7]\]. After selecting the mutant mice, hematopoietic cells were taken from their orbital sinus, and GFP-negative cells were sorted. Then, genotyping PCR was performed to identify the *Pdx1*^−/−^ mice using the sorted GFP-negative cells.

Glucose tolerance test
----------------------

All the mice were fasted for at least 16 h before the study. Then, they were challenged with an oral glucose dose of 1.0 mg/g body weight. Blood samples were taken from the retro-orbital sinus using a heparinized capillary tube at 0, 5, 15, 30, 60, 90, and 120 min after glucose administration, and blood glucose concentrations were measured using an automatic blood glucose meter (Arkray Inc., Kyoto, Japan). Blood samples at 0, 15, and 30 min after glucose administration were collected and centrifuged in heparinized tubes, and the plasma was stored at −20°C. A commercially available ELISA kit (Cat No. MS302; Morinaga Institute of Biological Science, Inc., Yokohama, Japan) was used to assay plasma insulin. *Pdx1*^+/−^ and IQI/Jic strain mice were used for comparisons with *PPO* mice. IQI/Jic strain mice were selected as the control because the genetic background of both the *Pdx1*^+/−^ mice and blastocysts to generate *PPO* mice was the IQI/Jic strain.

Fluorescence and phase contrast microscopy
------------------------------------------

A microscopy (VB-6010, Keyence, Osaka, Japan) and GFP filter (OP-42313, Keyence) were used to observe mouse internal organs under fluorescence and phase-contrast conditions (phase).

Immunohistochemistry
--------------------

Sections fixed in 10% buffered formalin and embedded in paraffin were mounted on silane-coated glass slides and immunostained by using a Leica Bond-Max automatic immunostainer (Leica Biosystems, Mount Waverley, VIC, Australia). Paraffin sections were dewaxed in a Bond Dewax solution and rehydrated in alcohol and Bond Wash solution (Leica Biosystems). Detection was performed using a Bond Polymer Refine Detection system. Then, the sections were counterstained with hematoxylin. Immunohistochemical analysis was performed with polyclonal rabbit anti-GFP (Product code ab290, Abcam plc, Cambridge, UK).

Reproduction and germline transmission
--------------------------------------

To confirm germline transmission, the chimeras were mated to intact IQI/Jic strain mice. GFP expression of the infants was detected with a microscopy (VB-6010, Keyence) and GFP filter (OP-42313, Keyence).

Results {#s3}
=======

Reproductive rates of chimeric mice
-----------------------------------

To generate chimeric mice, G-mESCs without the *Prdm14* and *Otx2* genes were injected into blastocysts obtained by crossing *Pdx1^+/^*^−^ male mice with *Pdx1^+/^*^−^ female mice. We genotyped GFP-negative peripheral blood molecular cells from 7-week-old infants. The *Pdx1*^−^*^/^*^−^ genotype was present in 20 of the 77 infants (26.0%, 12 males and 8 females) complemented by G-mESCs without the *Prdm14* and *Otx2* genes ([Table 1](#tbl_001){ref-type="table"}Table 1.Results of chimera mice by utilization of G-mESCs without *Prdm14* and *Otx2* genesGenotypingof recipientUsedG-mESCsNo. of embryostransferredNo. of chimerasGenotype of chimerasaNo. of chimerism (%)−/−+/−+/+MaleFemaleMaleFemaleMaleFemale\>50%\<50%100%*Pdx1*^+/--^× *Pdx1*^+/--^*Prdm14*^--/--^,*Otx2*^--/--^22077 (35.0%)128221215817 (22.1%)52 (67.5%)8 (10.4%)*Pdx1*^+/--^× *Pdx1*^+/--^*Prdm14*^+/+^,*Otx2*^+/+^(intact cells)18974 (39.1%)13926813518 (24.3%)46 (62.2%)10 (13.5%)). On the other hand, the *Pdx1*^−^*^/^*^−^ genotype was present in 22 of the 74 infants (29.7%, 13 males and 9 females) complemented by G-mESCs with *Prdm14* and *Otx2* genes ([Table 1](#tbl_001){ref-type="table"}). Fifteen of the *PPO* mice and 13 of the *Pdx1*^−^*^/^*^−^ mice complemented by G-mESCs with *Prdm14* and *Otx2* genes (control) were used for analysis ([Table 2](#tbl_002){ref-type="table"}Table 2.Number of chimerism in *Pdx1^−/−^* mice complemented by G-ESCs without *Prdm14* and *Otx2* genesGenotyping of recipientUsed G-mESCsGenderNo. of chimerism (%)0%\>50%\<50%100%*Pdx1^−/−^Prdm14*^−/−^, *Otx2*^−/−^Males3351Females2420*Pdx1^−/−^Prdm14*^+/+^, *Otx2*^+/+^(intact cells)Males23valign=\"top\"71Females2520). The 0% chimeras were excluded from further study. The remaining male control mice (including some \>50% chimeras) were used for preliminary investigation.

Characteristics of PPO mice
---------------------------

In immunohistochemical analysis, GFPs were detected from to the thyroid gland ([Fig. 2A](#fig_002){ref-type="fig"}Fig. 2.Characteristics of *PPO* mice. A--G. GFP immunohistochemistry in *PPO* mice; thyroid gland (A), lung (B), heart (C), liver (D), spleen (E), intestines (F), and kidney (G). H. Observations of the pancreas in a male *PPO* mouse under phase. The area enclosed by the dotted line indicates the pancreas reconstituted by G-mESCs. I. Observations of the pancreas in a male *PPO* mouse under GFP fluorescence. The area enclosed by the dotted line indicates the pancreas reconstituted by G-mESCs. J. GFP immunohistochemistry of the pancreas in *PPO* mice. K. GFP immunohistochemistry of the pancreas in *Pdx1*^+/−^ mice complemented by ES cells without the *Prdm14* and *Otx2* genes. L. Oral glucose tolerance test in male *PPO* mice at 10 weeks of age. M. Oral glucose tolerance test in female *PPO* mice at 10 weeks of age. Data are presented as the mean ± SE. \**P*\<0.05, \*\**P*\<0.01 (Student's *t-*test) compared with value for *Pdx1*^+/−^ and IQI/Jic strain mice. Black circles or trigonal marks represent *PPO* mice. Gray circles or trigonal marks represent *Pdx1*^+/−^. Open circles or trigonal marks represent intact mice (IQI/Jic strain). Scale bars represent the following distances: A, 100 *µ*m; B, C, E--G, J, and K: 200 *µ*m; and D, 400 *µ*m.), lung ([Fig. 2B](#fig_002){ref-type="fig"}), and heart ([Fig. 2C](#fig_002){ref-type="fig"}) in *PPO* mice. Additionally, the G-mESCs contributed to the liver ([Fig. 2D](#fig_002){ref-type="fig"}), spleen ([Fig. 2E](#fig_002){ref-type="fig"}), intestines ([Fig. 2F](#fig_002){ref-type="fig"}), and kidney ([Fig. 2G](#fig_002){ref-type="fig"}) in *PPO* mice, although they were not detected under a fluorescent microscope ([Fig. 2I](#fig_002){ref-type="fig"}). Upon observation under a fluorescent microscope, G-mESCs contributed to the pancreas highly in the abdominal cavity of the *PPO* mice ([Figs. 2](#fig_002){ref-type="fig"}H and I) and immunohistochemistry revealed high expressions of GFP in the pancreas of *PPO* mice ([Fig. 2J](#fig_002){ref-type="fig"}). On the other hand, the pancreatic reconstitution of *Pdx1*^−/+^ mice complemented by G-mESCs without the *Prdm14* and *Otx2* genes showed mosaicism ([Fig. 2K](#fig_002){ref-type="fig"}). Additionally, impaired glucose tolerance of the *Pdx1*^−/−^ mice without the *Prdm14* and *Otx2* genes was improved by blastocyst complementation, although the male *Pdx1*^−/−^ mice showed impaired glucose tolerance ([Fig. 2L](#fig_002){ref-type="fig"}). Glucose tolerance test of female *Pdx1*^−/−^ mice also was same result ([Fig. 2M](#fig_002){ref-type="fig"}).

Evaluations of the contributions of G-mESCs without the Prdm14 and Otx2 genes to gametes and the brain in chimeric mice
-----------------------------------------------------------------------------------------------------------------------

G-mESCs without the *Prdm14* and *Otx2* genes did not contribute to spermatozoa and the testes in *Pdx1*^−/−^ mice ([Figs. 3A and B](#fig_003){ref-type="fig"}Fig. 3.Contributions of the G-ESCs without the *Prdm14* and *Otx2* genes to gametes and the brain. A. GFP immunohistochemistry of spermatozoa and testes in *PPO* mice. B. GFP immunohistochemistry of spermatozoa and testes in control mice. C. Observations of male reproductive organs under phase. Areas enclosed by dotted lines indicate the testes. There was no macroscopic difference between the *PPO* and control testis. D. Observations of male reproductive organs under GFP fluorescence. Areas enclosed by dotted lines indicate the testes. The GFP was not detected in the testis of *PPO* mice. E. Magnification of testes and epididymis in a *PPO* mouse under phase. Areas enclosed by dotted lines indicate testes of *PPO* and control mice. Arrows indicate the epididymides. F. Magnification of testis and epididymis in *PPO* mouse under GFP fluorescence. Areas enclosed by the dotted lines show testis in *PPO* and control. Arrows show the epididymis. G. GFP immunohistochemistry of the ovary in *PPO* mice. H. GFP immunohistochemistry of the ovary in control mice. I. Observations of female reproductive organs under phase. Areas enclosed by dotted lines indicate the ovaries. There was no macroscopic difference between the *PPO* and control ovary. J. Observations of female reproductive organs under GFP fluorescence. Areas enclosed by dotted lines indicate the ovaries. The GFP was not detected in the ovary of *PPO* mice. K. Magnification of female reproductive organs in the *PPO* mouse under phase. Areas enclosed by dotted lines indicate the ovaries in the *PPO* mouse. Arrows indicate the oviducts. L. Magnification of female reproductive organs in the *PPO* mouse under GFP fluorescence. Areas enclosed by dotted lines indicate the ovaries in the *PPO* mouse. Arrows indicate the oviducts. M. GFP immunohistochemistry of the brain in *PPO* mice. N. GFP immunohistochemistry of the brain in control mice. O. Observations of the brain in *PPO* mice and control mice under phase. There was no macroscopic difference between the *PPO* and control brain. P. Observations of the brain in *PPO* mice and control mice under GFP fluorescence. The GFP was not detected in the brain of *PPO* mice. Scale bars represent the following distances: A, B, G, and H, 100 *µ*m; M and N, 400 *µ*m.), although they did contribute to other reproductive organs ([Figs. 3C--F](#fig_003){ref-type="fig"}). G-mESCs without the *Prdm14* and *Otx2* genes did not contribute to oocytes, ovirio cells, and ovaries in the *Pdx1*^−/−^ mice without the *Prdm14* and *Otx2* genes ([Figs. 3G and H](#fig_003){ref-type="fig"}), although they did contribute to oviducts and uterus ([Figs. 3I--L](#fig_003){ref-type="fig"}), which was similar to the case in the control mice. Additionally, G-mESCs without the *Prdm14* and *Otx2* genes did not contribute to the brain ([Figs. 3M--P](#fig_003){ref-type="fig"}).

Reproduction and germline transmission in PPO mice
--------------------------------------------------

The fertility rates ([Fig. 4A](#fig_004){ref-type="fig"}Fig. 4.Reproduction and germline transmission in *PPO* mice. A. Fertility rates and number of infants. B. Rates of GFP-positive infants from *PPO* and control mice. The rates were analyzed by χ^2^-test. \*\*Significant difference of *P*\<0.01. C. Confirmation of germline transmission.) and the number of infants produced by the male and female *PPO* mice did not differ from those of the control mice. Of the 80 male and 77 female infants produced by the control mice, the numbers of male and female GFP-positive infants were 55 (68.7%) and 21 (27.2%), respectively ([Fig. 4B](#fig_004){ref-type="fig"}). On the other hand, of the 74 male and 73 female infants produced by the *PPO* mice ([Fig. 4B](#fig_004){ref-type="fig"}), none of the infants showed GFP fluorescence ([Fig. 4C](#fig_004){ref-type="fig"}).

Discussion {#s4}
==========

Studies examining blastocyst complementation using human PS cells are promoted by the Nakauchi group \[[@r13]\]. In recent years, Kobayashi *et al.* (2015) successfully limited and controlled PS cells for endoderm organs, especially the pancreas, via the inducible expression of the *Milx1* gene, a transcription factor that induces differentiation of animal PS cells into the endoderm \[[@r14]\]. In the present study, we established a novel blastocyst complementation technique utilizing human PS cells as donor cells.

There is a concern in Japan that blastocyst complementation using human PS cells as donor cells may contribute to the central nervous systems of experimental animals, specifically that the contribution of human stem cells to the brain may lead to the generation of mice with human-like intelligence. Although this may seem unlikely, the possibility cannot be completely ruled out; therefore, it is necessary to address this problem. In a study conducted by Tian *et al.* (2002) \[[@r22]\], *Otx2*-deficient mouse embryos did not develop heads. From this finding, we hypothesized that *Otx2*-deficient mESCs would be unlikely to contribute to the brain in chimeric mice. Indeed, our results showed that G-mESCs without the *Prdm14* and *Otx2* genes did not contribute to the brains of chimeric mice, which addresses one of the concerns surrounding the use of human stem cells as donor cells for blastocyst complementation.

A second concern regarding blastocyst complementation using human stem cells as donor cells is that these cells may contribute to the gametes, leading to the generation of humanized gametes and potentially a new form of life. Yamaji *et al.* (2008) showed that the *Prdm14* gene was associated with the development of germ cells in mice and that *Prdm14*-deficient mice displayed a lack of germ cells \[[@r25]\]. In the present study, the gametes, testes, and ovaries of *PPO* mice were also formed by recipient cells. In the previous study by Yamaji *et al.* (2008), the testes and ovaries in *Prdm14*-deficient mice were shown to exhibit atrophy \[[@r25]\]. Therefore, *Prdm14*-deficient ES cells may be unlikely to contribute to the gametes, testes, or ovaries. In addition, female chimeras were considered to be theoretically unable to achieve germline transmission \[[@r2]\] because the karyotype of the ES cells used (EGR-G101) was XY. However, our female chimeras derived from XY ES cells achieved germline transmission in similar to previous study \[[@r15]\], as did the male and female chimeras derived from G-mESCs with *Prdm14* and *Otx2* genes obtained in our study. On the other hand, the G-mESCs without the *Prdm14* and *Otx2* genes successfully interrupted germline transmission from the male and female chimeras. These results address the second concern about blastocyst complementation using human stem cells as donor cells. Thus, we hypothesized that the utilization of *Prdm14*-deficient ES cells could lead to the development of blastocyst complementation technology that does not contribute to gametes.

In the present study, CRISPR/Cas9 was used to delete the *Prdm14* and *Otx2* genes from a mouse model. CRISPR/Cas9 cut genomic DNA homozygosity \[[@r19], [@r21]\], as did the normal gene targeting methods \[[@r8]\]. However, homologous recombination via CRISPR/Cas9 was more efficient than that achieved using normal gene targeting methods \[[@r10]\]. Therefore, the CRISPR/Cas9 gene knockout method is suitable for use in blastocyst complementation technology, as the phenotype of the ES cells was expressed in the chimeric mice. Additionally, the pancreata of *Pdx1*^−/−^ mice were complemented by G-mESCs without the *Prdm14* and *Otx2* genes. These findings revealed that PDX-1-deficient blastocyst complementation improved the impaired glucose tolerance, which is in agreement with the results of previous studies indicating that mouse blastocyst complementation using rat iPS cells improved diabetes in *Pdx1*^−/−^ mice \[[@r13]\] and that transplantation of rat pancreata via rat blastocyst complementation using mouse iPS cells improved streptozotocin-induced diabetes in mice \[[@r24]\]. Therefore, we believe that blastocyst complementation using ES cells without the *Prdm14* and *Otx2* genes may offer an effective approach for studies using human stem cells \[[@r12], [@r23]\], ES cells, iPS cells, and other types of cells.
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